Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES ‐1 by enmetazobactam and tazobactam
FEBS Letters · 2025-11 · 599 (22) · 3284-3300
DOI: 10.1002/1873-3468.70155 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, online erschienen am 13.09.2025. Verfasst von Michael Beer und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: beta-Lactamases, beta-Lactamase Inhibitors, Penicillanic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council, BLRD VA.
Abstract (Originalsprache)
β‐Lactamase‐catalysed hydrolysis is the primary form of β‐lactam antibiotic resistance in Gram‐negative bacteria. The penicillanic acid sulfone (PAS) enmetazobactam is thought to inhibit extended‐spectrum β‐lactamases (ESBLs) by fragmentation of an initial acyl‐enzyme to form an active‐site lysinoalanine cross link. We investigate interactions of enmetazobactam and its congener tazobactam with GES‐1, an ESBL with structural features of carbapenem‐hydrolysing β‐lactamases. Crystal structures show different breakdown products of the two inhibitors covalently bound to the catalytic Ser70, assigned using quantum mechanics/molecular mechanics (QM/MM) calculations. We find no evidence for lysinoalanine formation, with mass spectrometry indicating active enzyme regeneration, behaviour previously observed for carbapenem‐hydrolysing enzymes, but not ESBLs. This work establishes that PAS inhibitors interact with diverse β‐lactamases by differing mechanisms, which should inform development of future compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
- Centre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, UK.
- Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, OH, USA.
- Department of Biology and Biochemistry, 4 South, University of Bath, Bath, UK.
- School of Biochemistry, University of Bristol, Bristol, UK.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
ORCID-Profile: Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R Bethel, Catherine L Tooke, Marc W Van der Kamp, Krisztina M Papp-Wallace, Robert A Bonomo, Stuart Shapiro, Adrian J Mulholland, James Spencer
Förderung
- Biotechnology and Biological Sciences Research Council
- Engineering and Physical Sciences Research Council
- BLRD VA
- Cleveland Department of Veterans Affairs
- HORIZON EUROPE European Research Council
Zitieren
APA
Beer, M., Hinchliffe, P., Hanževački, M., Bethel, C. R., Tooke, C. L., Van der Kamp, M. W., Papp-Wallace, K. M., Bonomo, R. A., Shapiro, S., Mulholland, A. J., & Spencer, J. (2025). Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES ‐1 by enmetazobactam and tazobactam. FEBS Letters, 599(22), 3284-3300. https://doi.org/10.1002/1873-3468.70155
Vancouver
Beer M, Hinchliffe P, Hanževački M, Bethel CR, Tooke CL, Van der Kamp MW, et al. Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES ‐1 by enmetazobactam and tazobactam. FEBS Letters. 2025;599(22):3284-3300. doi:10.1002/1873-3468.70155
BibTeX
@article{Beer2025,
author = {Beer, Michael and Hinchliffe, Philip and Hanževački, Marko and Bethel, Christopher R and Tooke, Catherine L and Van der Kamp, Marc W and Papp-Wallace, Krisztina M and Bonomo, Robert A and Shapiro, Stuart and Mulholland, Adrian J and Spencer, James},
title = {Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES ‐1 by enmetazobactam and tazobactam},
journal = {FEBS Letters},
year = {2025},
volume = {599},
number = {22},
pages = {3284--3300},
doi = {10.1002/1873-3468.70155}
}
EUVIMED